Related Experiment Video

Updated: Jan 21, 2026

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.5K

[Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer]

Takashi Kawahara1

  • 1Dept. of Urology, Faculty of Medicine, University of Tsukuba.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 19, 2026
PubMed

Insights

Non-muscle invasive bladder cancer (NMIBC) affects many patients, often treated with TURBT and intravesical therapy. This review focuses on new phase III trials for BCG-naïve NMIBC, exploring emerging treatments beyond traditional methods.

Area of Science:

  • Urology
  • Oncology
  • Clinical Trials

Background:

  • Non-muscle invasive bladder cancer (NMIBC) constitutes approximately 70% of all bladder cancer diagnoses.
  • Standard treatment involves transurethral resection of bladder tumor (TURBT) followed by intravesical therapy, tailored to recurrence risk.
  • Bacillus Calmette-Guérin (BCG) is a key intravesical therapy, but a significant portion of patients become BCG-unresponsive, often necessitating radical cystectomy.

Purpose of the Study:

  • To review recent and ongoing phase III clinical trials for BCG-naïve NMIBC.
  • To highlight novel therapeutic strategies emerging for NMIBC.
  • To provide an overview of the current landscape and future directions in NMIBC treatment.

Main Methods:

  • Literature review of recent and ongoing phase III clinical trials.
  • Focus on trials involving patients with BCG-naïve NMIBC.
  • Analysis of emerging therapeutic modalities, including immune checkpoint inhibitors, drug-delivery devices, and gene therapy.

Main Results:

  • Emerging therapies show promise in clinical trials for NMIBC.
  • Novel approaches aim to improve outcomes for BCG-naïve patients.
  • Ongoing phase III trials are evaluating the efficacy and safety of new treatments.

Conclusions:

  • The treatment paradigm for NMIBC is evolving with the advent of novel therapies.
  • Phase III trials are crucial for validating new treatment options for BCG-naïve NMIBC.
  • Future management of NMIBC may involve a broader range of therapeutic options beyond traditional intravesical instillations.

More Related Videos

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts08:15

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

16.4K
Culture of Bladder Cancer Organoids as Precision Medicine Tools08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Urinary Bladder01:23

Urinary Bladder

The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
3.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K